Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease: The CLARICOR trial

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Managing patients on direct factor Xa inhibitors with rapid thrombelastography

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Denosumab vs. zoledronic acid treatment in post-menopausal breast cancer: a 2-year prospective observational study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Plasma glycerol levels in men with hypertriglyceridemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Quantification of biotin in plasma samples by column switching liquid chromatography - tandem mass spectrometry

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Reference intervals for 12 clinical laboratory tests in a Danish population: The Lolland-Falster Health Study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Objectives. To elucidate the prognostic power of serum osteoprotegerin (OPG) in patients with stable coronary artery disease (CAD). Methods. Serum OPG levels were measured in the CLARICOR trial cohort of 4063 patients with stable CAD on blood samples drawn at randomization. The follow-up was 2.6 years for detailed cardiovascular events and 6 years for all-cause mortality. Results. OPG levels were significantly increased in non-survivors (21%) compared to survivors (median [quartiles] 2092 ng/L [1636; 2800] compared to 1695 ng/L [1322; 2193, p < 0.0001]). The 2.6-year follow-up showed that OPG adds to the prediction of both cardiovascular and all-cause mortality in combination with clinical risk factors (HR [one log10 unit increase] 6.1 [95% CI 2.4-15.6, p = 0.0001]) and HR 6.5 [95% CI 3.4-12.5, p < 0.0001], respectively). Similar, in the 6-year follow-up, OPG was found to be a strong predictor for all-cause mortality. Importantly, OPG remained an independent predictor of mortality even after adjustment for both clinical and conventional cardiovascular risk markers (HR 2.5 [95% CI 1.6-3.9, p < 0.0001]). Conclusions. Serum OPG has a long-lasting independent predictive power as to all-cause mortality and cardiovascular death in patients with stable CAD.

Original languageEnglish
JournalScandinavian Journal of Clinical & Laboratory Investigation
Volume74
Issue number8
Pages (from-to)657-664
ISSN0036-5513
DOIs
Publication statusPublished - 15 Jul 2014

ID: 44440474